<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819000</url>
  </required_header>
  <id_info>
    <org_study_id>PM032</org_study_id>
    <nct_id>NCT00819000</nct_id>
  </id_info>
  <brief_title>Therapy Optimization in Multiple Sclerosis (MS)</brief_title>
  <acronym>TOP MS</acronym>
  <official_title>TOP MS is a Study of Multiple Sclerosis Disease Management in Collaboration With Specialty Pharmacies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Neuroscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if higher compliance and adherence rates to drug
      therapy for MS result in better health outcomes than lower rates of therapy compliance and
      adherence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship of therapy Medication Possession Ratio (MPR), to patient outcomes</measure>
    <time_frame>12 months and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship of therapy adherence, defined as the accumulation of time from initiation to discontinuation of therapy and measured by time, to patient outcomes</measure>
    <time_frame>12 months and 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2878</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Treated MS Subjects</arm_group_label>
    <description>Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b</intervention_name>
    <description>MS therapies (listed above) used according to prescribers' instructions.</description>
    <arm_group_label>Treated MS Subjects</arm_group_label>
    <other_name>Copaxone®</other_name>
    <other_name>Avonex®</other_name>
    <other_name>Rebif®</other_name>
    <other_name>Betaseron®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their
        therapy from one of the participating Specialty Pharmacies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age or older, with a diagnosis of MS.

          -  Being treated with Glatiramer Acetate (GA) or (IFN)-β

          -  Receiving therapy from a participating Specialty Pharmacy

        Exclusion Criteria:

          -  Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become
             pregnant, or breast feeding during the study

          -  Has received an experimental drug in the last thirty (30) days other than Fampridine
             SR (4-aminopyridine or 4-AP)

          -  Unlikely to be able to participate for the full two years of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MerriKay Oleen-Burkey, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Teva Neuroscience, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Zwibel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neurologic Center of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site</name>
      <address>
        <city>Swartz Creek</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Specialty Pharmacy</keyword>
  <keyword>Therapy Management</keyword>
  <keyword>Medication Compliance</keyword>
  <keyword>Medication Adherence</keyword>
  <keyword>Medication Persistence</keyword>
  <keyword>Health Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

